JPMorgan analyst Alexei Gogolev initiated coverage of Enfusion with a Neutral rating and $12 price target. The analyst prefers shares of Clearwater Analytics (CWAN) over Enfusion, citing the former’s proven execution track record and expectation that it may become a Rule of 40 company by 2024. The firm adds that customers of financial services software providers are not immune to macro headwinds and stock market volatility.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ENFN: